

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
03 FEB 14 AM 11:00

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name The OB-C Group, LLC			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1350 Eye Street, NW Suite 690 City Washington State/Zip (or Country) DC 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Celeste Dembowski	Telephone 202-898-4746	E-mail (optional) cdembowski@ob-cgroup.com	5. Senate ID # 29802-366
7. Client Name <input type="checkbox"/> Self Biotechnology Industry Organization			6. House ID # 30108032

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$140,000.00</u> Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of methods.
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6011 of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code

Signature _____ Date 2/13/2008

Printed Name and Title Celeste Dembowski - Office Administrator F

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

H.R.2051, To provide for the establishment of regional plant genome and gene expression research and development centers., NSF plant genome and gene expression research and development.

H.R.2343, Biotechnology and Agriculture in the Developing World Act of 2001, entire bill.

H.R.4812, Genetically Engineered Crop and Animal Farmer Protection Act of 2002, entire bill.

S.2499, Food Allergen Consumer Protection Act, entire bill.

S.3095, Genetically Engineered Foods Act, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 4/15/2008

Printed Name and Title Celeste Dembowski - Office Administrator Pg

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R.2215, 21st Century Department of Justice Appropriations Authorization Act, entire bill.

H.R.5120, Treasury and General Government Appropriations Act, 2003, drug pricing amendment.

H.R.5236, Agriculture Appropriations Act, FDA issues.

S.2740, Treasury and General Government Appropriations Act, 2003, drug pricing amendment.

S.2766, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2003, HHS issues.

S.2778, Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2003, PTO issues.

S.2801, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2003, FDA issues.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2005

Printed Name and Title Celeste Dembowski - Office Administrator Pg

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

1

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R.3966, Genomic Science and Technology Innovation Act of 2002, entire bill.

H.R.3967, Genomic Research and Diagnostic Accessibility Act of 2002, entire bill.

S.1104, Trade Promotion Act of 2001, entire bill.

S.1611, Intellectual Property Protection Restoration Act of 2001, entire bill.

S.1754, Patent and Trademark Office Authorization Act of 2002, entire bill.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/15/2005

Printed Name and Title Celeste Dembowski - Office Administrator }

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code DEF (one per page)

16. Specific Lobbying issues

H.R.3448, Public Health Security and Bioterrorism Response Act of 2001, entire bill.

H.R.5005, Homeland Security Act of 2002, bioterrorism and related issues.

S.2452, National Homeland Security and Combatting Terrorism Act of 2002, entire bill.

S.3148, Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2002, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENG (one per page)

16. Specific Lobbying issues

**** , no specific bill, funding for research and development to develop advanced biotech energy and chemicals , no specific bill, biobased purchasing policy.**

H.R.4, SAFE Act of 2001 Securing America's Future Energy Act of 2001, entire bill.

S.517, National Laboratories Partnership Improvement Act of 2001, entire bill.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 4/15/2005

Printed Name and Title Celeste Dembowski - Office Administrator P

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code IMM (one per page)
16. Specific Lobbying issues
 H.R.3130, Technology Talent Act of 2001, H-1B visas.
 S.1549, Technology Talent Act of 2001, H-1B visas.

17. House(s) of Congress and Federal agencies contacted
 House of Representatives
 Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.4954, Medicare Modernization and Prescription Drug Act of 2002, entire bill.

H.R.5450, Beneficiary Access to Care Act of 2002, entire bill.

S.2625, Medicare Outpatient Prescription Drug Act of 2002, entire bill.

S.2729, 21st Century Medicare Act, entire bill.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

S.1765, Bioterrorism Preparedness Act of 2001, entire bill.

S.2049, Childhood Vaccine Supply Act of 2002, entire bill.

S.2328, SMART Mom Act Safe Motherhood Act for Research and Treatment, entire bill.

S.2394, A bill to amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information to pediatric patients., entire bill.

S.2677, Consumer Access to Prescription Drugs Improvement Act of 2002, entire bill.

S.812, Greater Access to Affordable Pharmaceuticals Act of 2001, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P:

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

******, no specific bill, xenotransplantation.

*****, no specific bill, gene therapy research.

H.R.1372, Human Cloning Research Prohibition Act, human cloning prohibition issues.

H.R.1644, Human Cloning Prohibition Act of 2001, human cloning prohibition issues.

H.R.2059, Stem Cell Research Act of 2001, human cloning prohibition issues.

H.R.2172, Cloning Prohibition Act of 2001, cloning prohibition issues.

H.R.2505, Human Cloning Prohibition Act of 2001, human cloning prohibition issues.

H.R.2608, Cloning Prohibition Act of 2001, human cloning prohibition issues.

H.R.2863, Cell Development Research Act of 2001, human cloning prohibition issues.

S.1899, Human Cloning Prohibition Act of 2001, human cloning prohibition issues.

S.2439, Human Cloning Prohibition Act of 2002, human embryonic stem cell generation and research issues.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
16	Lobbying Issues	S.2531, Human Tissue Transplant Safety Act of 2002, human cloning prohibi
		issues.
16	Lobbying Issues	S.790, Human Cloning Prohibition Act of 2001, human cloning prohibition is
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

1

F

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

**** , no specific bill, vaccine tax credit.**

*** , no specific bill, Research and Development tax credits.**

H.R.1298, Orphan Drug Tax Credit Act of 2001, tax credits.

H.R.2153, American Breakthrough Research Act of 2001, net operating loss issues.

H.R.2383, To amend the Internal Revenue Code of 1986 to increase and modify the exclusion relating to qualified business stock and to provide that the exclusion relating to incentive stock options will no longer be a minimum preference., small business stock and tax issues.

S.1049, American Breakthrough Research Act of 2001, net operating loss issues.

S.1341, A bill to amend the Internal Revenue Code of 1986 to expand human clinical trials qualifying for the credit, and for other purposes., orphan drug tax credit.

S.455, Encouraging Investment in Small Business Act, encouraging investments in small business, tax credits

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/13/2003

Printed Name and Title Celeste Dembowski - Office Administrator P:

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R.2149, Trade Promotion Authority Act of 2001, drug reimportation.

H.R.3009, Andean Trade Promotion and Drug Eradication Act, drug reimportation.

S.1104, Trade Promotion Act of 2001, drug reimportation.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas	
McKernan, Kim F.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature Celeste Dembowski Date 2/13/2003
Printed Name and Title Celeste Dembowski - Office Administrator Pag

Registrant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

